http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006504665-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-32 |
| filingDate | 2003-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2006-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2006504665-A |
| titleOfInvention | Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| abstract | The present invention relates to a compound defined by formula (I) or a pharmaceutically acceptable salt thereof wherein R 1 , Q, Y, R 2 , R 3 , R 4 , R 5 and n are as defined herein. provide. The present invention also provides a pharmaceutical composition comprising a compound of formula (I) as defined herein or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier, diluent or excipient. The invention also provides a method of inhibiting an MMP-13 enzyme in an animal comprising administering to the animal a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides a method of treating a disease mediated by an MMP-13 enzyme in a patient comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition. I will provide a. The present invention also includes administering to a patient a compound of formula (I) or a pharmaceutically acceptable salt thereof, alone or in a pharmaceutical composition, for heart disease, multiple sclerosis, osteoarthritis and chronic joints in a patient. Rheumatism, osteoarthritis and arthritis other than rheumatoid arthritis, heart failure, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal disease, psoriasis, atherosclerosis and osteoporosis A method of treating a disease such as The present invention also provides a formulation comprising a compound of formula I or a pharmaceutically acceptable salt thereof together with other pharmaceutically active ingredients described herein. [Chemical 1] |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10005739-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012524884-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2015060373-A1 |
| priorityDate | 2002-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 656.